Maternal Smoking Intensity During Pregnancy and Early Adolescent Cardiovascular Health.

Background: The adverse cardiovascular effects of smoking are well established. We aimed to investigate the less well-understood effects of pregnancy smoke exposure on offspring cardiovascular health in early adolescence.

Methods And Results: Data were drawn from the nationally representative Longitudinal Study of Australian Children's Child Health CheckPoint.

Body Composition, Body Mass, and Cardiovascular Health in Mid-Childhood and Midlife: A Compositional Data Analysis.

We aimed to quantify associations of cardiovascular (CV) large and small artery measures with body composition and body mass (1) separately and (2) in combination in 11- to 12-year-old children and their parents. In the population-based cross-sectional Child Health CheckPoint study (1495 children, mean 12 ± 0.4 years, 49.

Identifying priorities and developing collaborative action plans to improve accessible housing practice, policy, and research in Canada.

This article describes the development of priorities and actions to improve the state of research, policy, and practice related to accessible housing in Canada for persons with disability or with accessible housing needs. A modified Delphi approach with an expert cross-sectoral panel was used to gain convergence on a set of priorities for advancing the accessible housing field in Canada. This included circulating an anonymous pre-meeting survey (N = 49) followed by an in-person planning meeting (N = 45).

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.

Background: GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk and progression of Parkinson's disease. We aimed to establish whether the GLP-1 receptor agonist, exenatide, could slow the rate of progression of Parkinson's disease.

Methods: We did a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial at six research hospitals in the UK.